title: Diabetes: HOME reveals new data on a cornerstone of treatment.
abstract: A question often asked by health-care providers is whether metformin has added benefits if continued after patients with type 2 diabetes mellitus switch to insulin. Beneficial effects on macrovascular end points observed in response to sustained metformin therapy argue in favor of this approach, according to new research from The netherlands.
authors.forename: William T
authors.initials: WT
authors.lastname: Cefalu
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin
references.citation: Diabetes Care. 2009 Jan;32(1):193-203
references.pmid: 18945920
references.citation: Diabetes Care. 2002 Dec;25(12):2133-40
references.pmid: 12453950
references.citation: Lancet. 1998 Sep 12;352(9131):837-53
references.pmid: 9742976
references.citation: N Engl J Med. 2008 Jun 12;358(24):2545-59
references.pmid: 18539917
references.citation: Obesity (Silver Spring). 2008 Oct;16(10):2323-30
references.pmid: 18719634
references.citation: N Engl J Med. 2009 Jan 8;360(2):129-39
references.pmid: 19092145
references.citation: Nat Med. 2004 Apr;10(4):355-61
references.pmid: 15057233
references.citation: N Engl J Med. 2008 Jun 12;358(24):2560-72
references.pmid: 18539916
references.citation: Arch Intern Med. 2009 Mar 23;169(6):616-25
references.pmid: 19307526